Julie E Ledgerwood

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
    Julie E Ledgerwood
    Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 208:418-22. 2013
  2. pmc Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
  3. doi request reprint A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
  4. pmc A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1396-404. 2011
  5. doi request reprint DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011
  6. pmc Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    Joseph P Casazza
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Infect Dis 207:1829-40. 2013
  7. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
  8. pmc DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults
    Surender Khurana
    Division of Viral Products, National Institute of Allergyand Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 208:413-7. 2013
  9. pmc Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
  10. pmc Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine
    Uzma N Sarwar
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, USA
    Travel Med Infect Dis 9:126-34. 2011

Collaborators

Detail Information

Publications13

  1. pmc Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
    Julie E Ledgerwood
    Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 208:418-22. 2013
    ..This study defines the shortest prime-boost interval associated with an improved response to MIV...
  2. pmc Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
    ..m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens...
  3. doi request reprint A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
    ..This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses...
  4. pmc A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1396-404. 2011
    ..There are no licensed vaccines to prevent WNV in humans. The safety and immunogenicity of a first-generation WNV DNA vaccine was demonstrated in a clinical trial and a similar DNA vaccine has been licensed for use in horses...
  5. doi request reprint DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Infect Dis 11:916-24. 2011
    ..We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improve antibody responses to inactivated influenza vaccination...
  6. pmc Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    Joseph P Casazza
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Infect Dis 207:1829-40. 2013
    ..The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy...
  7. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
    ..DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity...
  8. pmc DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults
    Surender Khurana
    Division of Viral Products, National Institute of Allergyand Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 208:413-7. 2013
    ..Enhanced HA1 binding and avidity after an interval of ≥12 weeks between prime and boost correlated with improved neutralization of homologous and heterologous H5N1 strains. Clinical trials registration NCT01086657. ..
  9. pmc Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
    ..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies...
  10. pmc Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine
    Uzma N Sarwar
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, USA
    Travel Med Infect Dis 9:126-34. 2011
    ..This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine...
  11. pmc Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses
    Christopher J Obara
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA
    Virology 437:20-7. 2013
    ..Altogether, our studies suggest that cellular attachment factor expression is not a significant contributor to the potency of neutralizing antibodies to flaviviruses...
  12. pmc Randomization to standard and concise informed consent forms: development of evidence-based consent practices
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    Contemp Clin Trials 33:895-902. 2012
    ....
  13. pmc Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    Yuxing Li
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 85:8954-67. 2011
    ..It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike...